Wave Life Sciences Ltd. - Ordinary Shares (WVE) News
Filter WVE News Items
WVE News Results
| Date | Symbol | Company | Title | Start | End | Change | POWR Rating | ||
|---|---|---|---|---|---|---|---|---|---|
| Loading, please wait... | |||||||||
WVE News Highlights
- For WVE, its 30 day story count is now at 5.
- Over the past 9 days, the trend for WVE's stories per day has been choppy and unclear. It has oscillated between 1 and 2.
- The most mentioned tickers in articles about WVE are WAVE, RNA and AAT.
Latest WVE News From Around the Web
Below are the latest news stories about WAVE LIFE SCIENCES LTD that investors may wish to consider to help them evaluate WVE as an investment opportunity.
Wave Life Sciences Announces Initiation of Dosing in Phase 2 FORWARD-53 Trial of WVE-N531 in Duchenne Muscular DystrophyFORWARD-53 is fully enrolled with potentially registrational dystrophin expression data expected in 2024 Previous clinical proof-of-concept data demonstrated highest level of exon skipping ever observed in the clinic and that WVE-N531 was present in myogenic stem cells, which are important for potential muscle regeneration CAMBRIDGE, Mass., Dec. 15, 2023 (GLOBE NEWSWIRE) -- Wave Life Sciences Ltd. (Nasdaq: WVE), a clinical-stage RNA medicines company committed to delivering life-changing treatme |
Wave Life Sciences Ltd.'s (NASDAQ:WVE) recent 35% pullback adds to one-year year losses, institutional owners may take drastic measuresKey Insights Institutions' substantial holdings in Wave Life Sciences implies that they have significant influence over... |
Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on ThursdayIt's time to start off Thursday with a breakdown of the biggest pre-market stock movers worth keeping an eye on this morning! |
Wave Life Sciences Prices $100 Million Public Offering of Ordinary SharesCAMBRIDGE, Mass., Dec. 07, 2023 (GLOBE NEWSWIRE) -- Wave Life Sciences Ltd. (Nasdaq: WVE), a clinical-stage RNA medicines company committed to delivering life-changing treatments for people battling devastating diseases, announced today the pricing of its previously announced underwritten public offering of 20,000,000 of its ordinary shares at a price to the public of $5.00 per ordinary share. Gross proceeds to Wave Life Sciences from the offering are expected to be approximately $100 million, b |
Wave Life Sciences Announces Proposed Public Offering of Ordinary Shares and Pre-Funded WarrantsCAMBRIDGE, Mass., Dec. 06, 2023 (GLOBE NEWSWIRE) -- Wave Life Sciences Ltd. (Nasdaq: WVE), a clinical-stage RNA medicines company committed to delivering life-changing treatments for people battling devastating diseases, announced today that it has commenced an underwritten public offering of $100 million in aggregate of its ordinary shares, and, to certain investors that so choose in lieu of ordinary shares, pre-funded warrants to purchase ordinary shares. In connection with the offering, Wave |
Wave Life Sciences Announces Initiation of Dosing in RestorAATion Clinical Program Evaluating First-Ever RNA Editing Candidate, WVE-006, for Alpha-1 Antitrypsin DeficiencyWVE-006 is uniquely designed to correct the disease-causing RNA mutation in AATD, thereby restoring circulation of wild-type M-AAT protein and reducing Z-AAT protein levels to address both lung and liver manifestations of the disease Wave earned $20 million USD milestone from GSK for initiation of dosing; eligible for additional development, launch, and sales-related milestones of up to $505 million for WVE-006 Proof-of-mechanism data in individuals with AATD, as measured by restoration of M-AAT |
Wave Life Sciences to Present at 6ᵗʰ Annual Evercore ISI HealthCONx ConferenceCAMBRIDGE, Mass., Nov. 22, 2023 (GLOBE NEWSWIRE) -- Wave Life Sciences Ltd. (Nasdaq: WVE), a clinical-stage RNA medicines company committed to delivering life-changing treatments for people battling devastating diseases, today announced that Paul Bolno, MD, MBA, President and Chief Executive Officer, is scheduled to participate in an analyst-led fireside chat at the 6th Annual Evercore ISI HealthCONx Conference in Miami, FL on Wednesday, November 29, 2023 at 3:50 p.m. ET. A live webcast of this |
Wave Life Sciences Ltd. (NASDAQ:WVE) Q3 2023 Earnings Call TranscriptWave Life Sciences Ltd. (NASDAQ:WVE) Q3 2023 Earnings Call Transcript November 10, 2023 Operator: Good morning and welcome to Wave Life Sciences Third Quarter 2023 Financial Results Conference Call. At this time, all participants are in a listen-only mode. As a reminder, this call is being recorded and webcast. Now I’ll turn the call over […] |
Analysts Just Made A Notable Upgrade To Their Wave Life Sciences Ltd. (NASDAQ:WVE) ForecastsWave Life Sciences Ltd. ( NASDAQ:WVE ) shareholders will have a reason to smile today, with the analysts making... |
WAVE Life Sciences Ltd (WVE) Reports Notable Shift to Profitability in Q3 2023Financial and Business Progress Highlighted in Latest Earnings Release |